[CAS NO. 33401-94-4] Pyranteltartrate
PRODUCTS SPECIFICATIONS [33401-94-4]
DESCRIPTION [33401-94-4]
Overview
| MDL | MFCD00216022 |
|---|---|
| Molecular Weight | 356.39 |
| Molecular Formula | C15H20N2O6S |
| SMILES | CN1CCCN=C1/C=C/C2=CC=CS2.O=C(O)[C@H](O)[C@@H](O)C(O)=O |
Summary
Pyrantel tartrate is an orally active anthelmintic and an agonist of the nicotinic acetylcholine receptor ( nAChR ). Pyrantel tartrate can cause spasmodic muscle paralysis in parasites. Pyrantel tartrate can be used in the study of parasitic infections such as ascariasis, hookworm infections, intestinal worms (pinworm infections), trichinosis and trichinosis [1] [2] .
In Vitro
Pyrantel tartrate (10 nM-10 µM; 72 h) shows good anti- A. suum and (0-168.2 M; 72 h) anti- N. americanus activity [1] [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | A. suum |
| Concentration: | 10 nM-10 µM |
| Incubation Time: | 72 h |
| Result: | Inhibited A. suum with a pEC 50 value of 7.24. |
Cell Viability Assay [2]
| Cell Line: | N. americanus |
| Concentration: | 0-168.2 M (0-100 µg/mL) |
| Incubation Time: | 72 h |
| Result: | Inhibited third-stage larvae and adult of N. americanus with IC 50 values of 2.0 and 7.6 mg/mL, respectively. |
In Vivo
Pyrantel tartrate (10 mg/kg; p.o.; single) reduces the worms in A. ceylanicum -infected hamsters, with the worm burden reduction of 87.2% and worm expulsion rate of 63.4% [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male Syrian Golden hamsters (3-week-old; A. ceylanicum -infected) [2] . |
| Dosage: | 10 mg/kg |
| Administration: | Oral administration; single. |
| Result: | Exhibited worm burden reduction and worm expulsion rates of 87.2% and 63.4%, respectively. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03278431 | Swiss Tropical & Public Health Institute |
Hookworm Infection
|
September 27, 2017 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : ≥ 34 mg/mL ( 95.40 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8059 mL | 14.0296 mL | 28.0591 mL |
| 5 mM | 0.5612 mL | 2.8059 mL | 5.6118 mL |
| 10 mM | 0.2806 mL | 1.4030 mL | 2.8059 mL |
References
- [1] Martin RJ, et, al. Oxantel is an N-type (methyridine and nicotine) agonist not an L-type (levamisole and pyrantel) agonist: classification of cholinergic anthelmintics in Ascaris. Int J Parasitol. 2004 Aug;34(9):1083-90.
- [2] Tritten L, et, al. In vitro and in vivo efficacy of Monepantel (AAD 1566) against laboratory models of human intestinal nematode infections. PLoS Negl Trop Dis. 2011 Dec;5(12):e1457.
Synonyms
